Fundraising Overview - The company raised a total of RMB 71,327.04 million from the issuance of 23.34 million shares at a price of RMB 30.56 per share, with a net amount of RMB 63,994.55 million after deducting issuance costs of RMB 7,332.49 million [1][2] - As of June 30, 2025, the remaining balance of unused raised funds is RMB 12,935.19 million, which includes RMB 235.19 million in the fundraising account and RMB 12,700.00 million in time deposits and financial products [2][3] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure the effective management and use of raised funds, including the establishment of dedicated bank accounts for fundraising [2][3] - The company signed tripartite and quadripartite supervision agreements with its subsidiaries and the sponsoring institution to clarify the rights and obligations of all parties involved [2][3] Fund Usage - The company has not used idle raised funds to temporarily supplement working capital during the reporting period [4][5] - The company has approved the use of up to RMB 16,000 million of idle raised funds for cash management, ensuring that it does not affect the normal progress of fundraising investment plans [5][6] - As of June 30, 2025, the company has invested RMB 12,700.00 million in various financial products, including transferable large-denomination certificates of deposit and structured deposits [5][6] Project Investment - The company has not made any early investments or replacements for fundraising investment projects during the reporting period [7] - The company has approved the use of part of the raised funds for new projects, including the development of a tumor companion diagnostic technology platform and a digital pathology and intelligent application development project, with an estimated investment of RMB 6,350.00 million [5][6] Remaining Funds - The company has a remaining balance of RMB 10,732.55 million in excess raised funds, which is not applicable for permanent working capital supplementation or loan repayment [6][7]

证券代码：688393 证券简称：安必平 公告编号：2025-034 广州安必平医药科技股份有限公司 关于暂时调整部分募集资金投资项目闲置场地用途的 公告 序号 项目 （万元） 额（万元） 基于肿瘤伴随诊断技术平台的应用开发项 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意广州安必平医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]1489 号），广州安必平医药科技股 份有限公司（以下简称"公司"）首次向社会公开发行人民币普通股（A 股）2,334 万股，每股发行价格 30.56 元，新股发行募集资金总额为 71,327.04 万元，扣除发 行费用 7,332.49 万元（不含增值税）后，募集资金净额为 63,994.55 万元。 上述募集资金已全部到位，并由中汇会计师事务所（特殊普通合伙）于 2020 年 8 月 14 日对本次发行的资金到账情况进行了审验，出具了《验资报告》（中汇会 验[2020]5523 号）。 二、募集资金使用情况 根据公司《首次公开发行股票并在科创板上市招股说明书》、《关于使用部分 超募资金投资建设新项目的公告》（公告编号：2022-039）、《关于 ...

Group 1 - The company will hold a half-year performance briefing on August 28, 2025, from 09:00 to 10:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Investors can submit questions from August 22 to August 27, 2025, and the company will address common concerns during the briefing [1][2] Group 2 - Key participants in the briefing include the Chairman and General Manager, Mr. Cai Xiangting, and other board members [2] - Investors can access the briefing online through the Shanghai Stock Exchange Roadshow Center [2][3] - After the briefing, investors can review the main content and outcomes on the Shanghai Stock Exchange Roadshow Center website [3]

Core Points - The company has completed the fundraising project "Application Development Project Based on Tumor Companion Diagnosis Technology Platform" and will use the remaining funds of 14,800 yuan to supplement working capital [1][5] - The total amount raised from the initial public offering was 713.27 million yuan, with a net amount of 639.95 million yuan after deducting issuance costs [1][2] - The project had a planned investment of 496.65 million yuan, with an actual investment of 367.55 million yuan, resulting in a surplus of 1.48 million yuan [2][3] Fundraising Overview - The company issued 23.34 million shares at a price of 30.56 yuan per share, raising a total of 713.27 million yuan [1][2] - The funds were stored in a dedicated account and managed under a regulatory agreement with the underwriter and the bank [2] Project Details - The project aimed to develop applications based on tumor companion diagnosis technology, with a total planned investment of 496.65 million yuan [2][3] - The actual investment was 367.55 million yuan, with a remaining surplus of 1.48 million yuan [3] Approval Process - The completion of the fundraising project and the use of surplus funds do not require board approval or explicit consent from the underwriter, as per the regulations [5]

Core Viewpoint - The company has approved the use of temporarily idle raised funds for cash management, not exceeding RMB 140 million, ensuring that it does not affect the normal implementation of fundraising investment plans [1][5]. Summary by Sections 1. Basic Situation of Raised Funds - The company raised a total of RMB 713.27 million from its initial public offering (IPO) by issuing 23.34 million shares at a price of RMB 30.56 per share, with all funds received and stored in a dedicated account [1]. 2. Investment Project Situation - The planned use of raised funds includes a project focused on the application development of a tumor companion diagnostic technology platform, with a total project cost of RMB 491.65 million and an intended use of RMB 453.62 million from the raised funds [2]. 3. Cash Management of Temporarily Idle Raised Funds - The company plans to use up to RMB 140 million of temporarily idle raised funds for cash management, ensuring that it does not impact the normal progress of fundraising investment projects. The funds can be used in a rolling manner within the specified limit [2][5]. - The investment period for this cash management is valid for 12 months from the date of board approval [3]. 4. Implementation Method - The board has authorized the chairman to exercise investment decision-making rights and sign relevant documents within the approved limit and validity period, with the finance department responsible for implementation [4]. 5. Distribution of Cash Management Earnings - Earnings from cash management will belong to the company and will be managed according to regulatory requirements, with funds returned to the dedicated account upon maturity [4]. 6. Review Procedures - The board and supervisory board have approved the cash management proposal, confirming compliance with relevant regulations and ensuring that it does not conflict with the construction of fundraising investment projects [5][6].

证券代码：688393 证券简称：安必平 公告编号：2025-037 广州安必平医药科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 "公司"）召开第四届董事会第九次会议,审议通过了《关于使用自有资金进行 现金管理的议案》，同意公司在确保不影响公司正常业务开展的情况下，使用额 度不超过人民币 22,000 万元的自有资金进行现金管理，用于购买安全性高、流 动性好、风险等级低的投资产品（包括但不限于结构性存款、定期存款、通知 存款、大额存单、协定存款等），且该等现金管理产品不得用于质押，不得实施 以证券投资为目的的投资行为。在上述额度内的资金可循环滚动使用。使用期 限自公司董事会审议通过之日起 12 个月内有效。 一、使用自有资金进行现金管理的概况 （一）现金管理目的 公司使用自有资金进行现金管理是为了提高公司资金使用效率，增加资产 收益，为公司及股东谋取更多回报，在保证公司正常经营所需流动资金的情况 下，提高资金利用效率，合理利用闲置资金，增加公司收益。 （三）现金管理额度及使用期限 公司计划使用不超过人民 ...

民生证券股份有限公司关于广州安必平医药科技股份有限公司 暂时调整部分募集资金投资项目闲置场地用途的核查意见 民生证券股份有限公司（以下简称"保荐机构"或"民生证券"）作为广州 安必平医药科技股份有限公司（以下简称"安必平"或"公司"）首次公开发行 股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上市公司募集资金监管规则》和《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对安 必平暂时调整部分募集资金投资项目闲置场地用途的相关事项进行了核查，发表 核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意广州安必平医药科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2020]1489 号），广州安必平医药科 技股份有限公司（以下简称"公司"）首次向社会公开发行人民币普通股（A 股） 扣除发行费用 7,332.49 万元（不含增值税）后，募集资金净额为 63,994.55 万 元。 上述募集资金已全部到位，并由中汇会计师事务所（特殊普通合伙）于 2020 年 8 月 14 日对本次发行的资金到账情况 ...

民生证券股份有限公司关于广州安必平医药科技 股份有限公司使用暂时闲置募集资金进行现金管理的核查意见 民生证券股份有限公司（以下简称"保荐机构"或"民生证券"）作为广州 安必平医药科技股份有限公司（以下简称"安必平"或"公司"）首次公开发行 股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上市公司募集资金监管规则》和《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对 安必平使用暂时闲置募集资金进行现金管理的相关事项进行了核查，发表核查 意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意广州安必平医药科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2020]1489 号），广州安必平医药 科技股份有限公司首次向社会公开发行人民币普通股（A 股）2,334 万股，每股 发行价格 30.56 元，新股发行募集资金总额为 71,327.04 万元，扣除发行费用 上述募集资金已全部到位，并由中汇会计师事务所（特殊普通合伙）于 （中汇会验[2020]5523 号）。公司已对上述募集资金进行了专户存储，具体 ...

Core Viewpoint - The report highlights a significant decline in the company's financial performance for the first half of 2025, primarily due to the impact of centralized procurement policies on the HPV product line, leading to a 30.11% decrease in revenue and a 176.38% drop in net profit compared to the same period last year [2][3][11]. Company Overview and Financial Indicators - Guangzhou Anbiping Medical Technology Co., Ltd. is focused on the pathology diagnosis industry, offering a comprehensive range of diagnostic reagents and automated equipment [2][4]. - The company reported a total revenue of approximately 159.40 million yuan, down from 228.07 million yuan in the same period last year, marking a 30.11% decrease [3][11]. - The total profit for the period was -18.49 million yuan, a decline of 333.51% compared to the previous year's profit of 7.92 million yuan [3][11]. - The net profit attributable to shareholders was -12.50 million yuan, down 176.38% from 16.36 million yuan in the previous year [3][11]. - The company’s net assets decreased by 1.94% to approximately 1.23 billion yuan compared to the end of the previous year [3][11]. Business Operations and Market Position - The company operates in the in vitro diagnostics (IVD) sector, specifically in pathology diagnosis, which is a critical area for cancer screening and diagnosis [8][11]. - The company has developed a full range of pathology diagnostic methods, including liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) [4][8]. - The company has received 12 new diagnostic-related registrations/approvals during the reporting period, bringing its total to over 600 [4][5]. - The company has established a marketing network covering over 2,500 medical institutions in China and has begun expanding into international markets [5][11]. Research and Development - The company invested approximately 21.25 million yuan in R&D, representing 13.33% of its revenue, focusing on AI applications in diagnostics and automation of pathology processes [12][14]. - The company has made significant advancements in AI-assisted diagnostic products, with a sensitivity of 85.8% for its cervical cytology AI, significantly higher than the 71.7% sensitivity of primary pathologists [14][22]. - The company has developed a fully automated liquid-based cytology workstation, XPro90, which streamlines the diagnostic process [20][21]. Industry Context - The pathology diagnosis industry is experiencing growth due to increasing cancer incidence rates, with over 4.82 million new cancer cases reported in China in 2022 [8][11]. - The company is positioned to benefit from national policies aimed at enhancing healthcare resource distribution and improving cancer screening and treatment [11][19]. - The company is actively involved in building pathology capabilities in collaboration with hospitals, focusing on personalized solutions for different healthcare settings [13][21].

广州安必平医药科技股份有限公司2025 年半年度报告摘要 公司代码：688393 公司简称：安必平 无 广州安必平医药科技股份有限公司 广州安必平医药科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司已在本报告中详细描述了公司可能面对的风险，具体内容敬请查阅本半年度报告"第三节管 理层讨论与分析"之"四、风险因素"。 说明 （有限合伙）的执行事务合伙人，持有广州市凯多投资咨询 中心（有限合伙）69.64%的合伙份额； 特佳睿安股权投资基金合伙企业（有限合伙）、杭州高特佳 睿海投资合伙企业（有限合伙）、杭州睿泓投资合伙企业（有 限合伙）、王海蛟为一致行动人； □适用 √不适用 第二节 公司基本情况 公司股票简况 | | 公司股票简况 | | | | --- | --- | --- | --- | | 股票种类 | 股票上市交易所 | 股票简称 股票代码 | 变更前股票简称 | | 上海证券交易所科 | | | | | A股 | 安必平 | 6 ...